Standard BioTools Appoints Alex Kim as Chief Financial Officer

FLDM 11.07.2024

Full Press ReleaseSEC FilingsOur FLDM Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
  • 01.08.2025 - Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 11.21.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SOUTH SAN FRANCISCO, Calif.,Nov. 07, 2024(GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment ofAlex Kimas Chief Financial Officer, effectiveNovember 11, 2024. Kim, a co-founder and most recently Chief Operating Officer ofStandard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization.

Michael Egholm, President and Chief Executive Officer ofStandard BioTools, said, “I am thrilled to announce Alex as our next CFO. Having co-foundedStandard BioToolswith me, Alex’s deep understanding of our business make him the clear choice for the role and he will continue to be a key architect in the design and implementation of our strategic and financial plans moving forward.”

Prior to joiningStandard BioTools, Kim was President of Milliken’s Healthcare Division, initially joining the company in 2015 as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development atPall Corporationand prior to that from 2002 to 2012, Kim worked at Danaher Corporation in a variety of roles across general management, M&A and business development. Over his career, Kim has completed over 40 transactions, largely focused on healthcare, medical technology and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business.

Kim said, “I am delighted to assume the CFO position and continue working alongside Michael and our talented team as we execute theStandard BioToolsvision. We have strong momentum and we are moving forward with steadfast focus on operational excellence to achieve our financial targets and long-term growth objectives.”

In connection with this appointment,Jonathan Mickelsen, Standard BioTools’ Vice President and Corporate Controller, has been appointed as the Company’s Vice President & Chief Accounting Officer.

AboutStandard BioTools Inc.

Standard BioTools Inc.(Nasdaq:LAB), the parent company ofSomaLogic Inc.and previously known asFluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes.Standard BioToolsworks with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more atstandardbio.comor connect with us on X, Facebook®, LinkedIn, and YouTubeTM.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply:standardbio.com/legal/salesterms.Patent and License Information:standardbio.com/legal/notices.Trademarks:standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024Standard BioTools Inc.(f.k.a.Fluidigm Corporation). All rights reserved.

Investor Contact:

David HolmesGilmartin Group LLC(332) 330-1031ir@standardbio.com

Primary Logo

Source: Standard BioTools Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com